ARTICLE | Company News

TPG regains Aptalis unit from Actavis

February 14, 2015 2:03 AM UTC

Private equity firm TPG will acquire Aptalis Pharmaceutical Technologies, a pharmaceutical outsourcing and R&D business within the Aptalis subsidiary of Actavis plc (NYSE:ACT), for an undisclosed amount. TPG said it intends to use the business "as a platform to enter into new partnerships and make additional acquisitions to grow the business." The firm declined to disclose further details.

Aptalis Pharmaceutical Technologies out-licenses prescription and OTC products and offers oral drug delivery platforms that address flavor and mouthfeel, increase bioavailability, and allow customized drug release. Forest Laboratories Inc., acquired by Actavis last year, purchased Aptalis Holdings Inc. from TPG for $2.9 billion in January 2014 (see BioCentury Extra, Feb. 18, 2014). ...